(Q79325600)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

Development of lactococcal GEM-based pneumococcal vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

Sandrine A L Audouy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Saskia van Selm

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Maarten L van Roosmalen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Eduard Post

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Rolf Kanninga

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Jolanda Neef

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Silvia Estevão

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Edward E S Nieuwenhuis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Peter V Adrian

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Kees Leenhouts

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Peter W M Hermans

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

18 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

2497-2506

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

Epidemiological differences among pneumococcal serotypes

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Molecular epidemiology of pneumococcal colonization in response to pneumococcal conjugate vaccination in children with recurrent acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Potential and opportunities for use of recombinant lactic acid bacteria in human health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Ability of Lactococcus lactis to export viral capsid antigens: a crucial step for development of live vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Novel surface display system for proteins on non-genetically modified gram-positive bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Development of antibodies against pneumococcal proteins alpha-enolase, immunoglobulin A1 protease, streptococcal lipoprotein rotamase A, and putative proteinase maturation protein A in relation to pneumococcal carriage and Otitis Media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Antibody-enhanced pneumococcal adherence requires IgA1 protease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Genome of the Bacterium Streptococcus pneumoniae Strain R6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Phagocytosis of unopsonized Pseudomonas aeruginosa by murine macrophages is a two-step process requiring glucose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Proinflammatory Bacterial Peptidoglycan as a Cofactor for the Development of Central Nervous System Autoimmune Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Lactic acid bacteria inducing a weak interleukin-12 and tumor necrosis factor alpha response in human dendritic cells inhibit strongly stimulating lactic acid bacteria but act synergistically with gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Gram-positive and Gram-negative bacteria elicit different patterns of pro-inflammatory cytokines in human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Bronchus- and nasal-associated lymphoid tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

NALT- versus Peyer's-patch-mediated mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Streptococcus pneumoniae polysaccharides conjugated to the outer membrane protein A from Klebsiella pneumoniae elicit protective antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Differential protein expression in phenotypic variants of Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

7 January 2021

Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

7 January 2021

Analysis of the specificity of bacterial immunoglobulin A (IgA) proteases by a comparative study of ape serum IgAs as substrates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

7 January 2021

A comprehensive genetic study of streptococcal immunoglobulin A1 proteases: evidence for recombination within and between species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.026

7 January 2021

10.1016/J.VACCINE.2006.09.026

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17081660%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference